Abbott's revenue has been flat over 15 months with steady Q3 EPS of $1.30, 7% growth, and upcoming Q4 international segment ...
We recently compiled a list of the 10 Best Investments During A Recession. The seventh stock on our list of best investments ...
Abbott is tapping the spirit of new beginnings for the New Year by unveiling a “gamechanger" feature within the company’s ...
A look at Exact Sciences Corporation’s acquisition by Abbott: review EXAS revenue growth, margins, and CRC/MRD screening ...
Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...
On Wednesday, the Reds Community Fund, St. Elizabeth Healthcare and Pitch In For Baseball & Softball (PIFBS) distributed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback